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1. Introduction 
Diabetes Mellitus is a syndrome characterized by hyperglycaemia and disturbances of 
carbohydrate, fat and protein metabolism associated with absolute or relative deficiencies in 
insulin secretion and, or insulin action.1 It is a genetically and clinically heterogeneous group 
of disorders that share glucose intolerance in common.2 It is the most common endocrine 
metabolic disorder world wide affecting people of all races and of different social 
conditions2. It is estimated that approximately 120 million people have diabetes mellitus 
worldwide and this number is expected to double in the next 25 year.4 The major part of the 
increase in the prevalence of diabetes mellitus is expected in the developing countries.5 In 
most African populations, it is said that the high prevalence of impaired glucose tolerance 
(IGT) suggests that public health impact of diabetes could increase in these communities in 
the future.6 
Diabetes mellitus is characterized by acute and long term complications and these result in 
increased morbidity and mortality in diabetics especially in developing countries due to 
inadequate facilities for treatment and the inability of patients to afford the cost of care.7 The 
cardiovascular, renal, retinal and neuropathic long-term complications lead to premature 
disability and death.7 
Heart disease has been singled out as a major cause of death in patients with diabetes 
mellitus,8,9 and the risk of atherosclerotic coronary artery disease is substantially increased 
in patients with both overt diabetes and asymptomatic hyperglycaemia.10 Several studies 
have suggested that diabetes may be associated with left ventricular (LV) structural and 
functional abnormalities in addition to, and independent of atherosclerosis.11,12 In the 
Framingham Cohort, diabetes was associated with higher LV mass in women but not men13. 
High blood pressure (BP), obesity and abnormal lipid profile, which often co-exist with 
diabetes, tend to be associated with preclinical cardiovascular abnormalities,14 and may 
contribute to the association of diabetes mellitus with cardiovascular events. 
However, there is increasing evidence that diabetics have abnormalities of left ventricular 
function in the absence of clinical heart disease15,16 which is an entity called diabetic 
cardiomyopathy.  
Diastolic left ventricular abnormalities have been disclosed in the past by cardiac 
catheterisation17 and abnormal systolic time interval using phonocardiograms,18,19 and 
presently by abnormal left ventricular filling using standard and digitised 
echocardiography,20,21 radionuclide studies22 and subsequently by Doppler 
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echocardiography.22,23. Non-invasive methods of assessing left function have confirmed that 
it is frequently impaired in young asymptomatic diabetics,24,25 in maturity onset diabetics 26 
and in those with retinopathy and nephropathy.27,28 In diabetes, the left ventricle is not 
usually dilated or hypertrophied29 and abnormalities of function are predominantly in 
diastole, with delayed opening of the mitral valve. Reduced ejection and abnormal systolic 
function is probably a late event.19,20 
Possible mechanisms for diabetic cardiomyopathy include excessive myocardial fibrosis,30 
interstitial accumulation of glycoproteins and slow sarcoplasmic calcium reuptake31 or 
altered release from a dysfunctional coronary endothelium of mediators such as nitric oxide 
and endothelin which exert paracrine myocardial effects on diastolic properties 32,34. 
2. Diastolic dysfunction 
2.1 What is diastolic dysfunction? 
Diastolic dysfunction can be defined as a condition in which myocardial relaxation and 
filling are impaired and incomplete.34 In its most severe form, diastolic dysfunction results 
in overt symptoms of congestive heart failure.35 In modest cases, symptoms of dyspnoea 
and fatigue occur only during stress or activity such as exercise when heart rate and/or end 
diastolic volume increase36. In its mildest forms, diastolic dysfunction can be manifested as 
slow or delayed pattern of relaxation and filling with little or no elevation in diastolic 
pressure and no cardiac symptoms.37 Some factors that have been implicated in left 
ventricular diastolic dysfunction include: diabetes mellitus, coronary artery disease, 
hypertensive heart disease, hypertrophic cardiomyopathy, valvular heart disease, cardiac 
transplantation, cardiac amyloidosis 38 and aging.39 
2.2 Prevalence of diastolic dysfunction 
The prevalence of asymptomatic diastolic dysfunction was estimated at 27% in an   
epidemilogic study, and was found to increase with age 40. Results of early studies 
suggested that as many as 40% of patients with heart failure symptoms have diastolic heart 
failure. More recent studies showed that of patients hospitalised for heart failure, 35% to 
40% present with diastolic heart failure.41,42 In the community setting, this number was 
found to be between 45%and 55%.43,44 Two recent studies found the prevalence of diastolic 
heart failure in women to be 1.5-to 2-fold greater than in men.45,46. In a study of 86 
normotensive type 2 diabetic patients (43% of whom were women, mean age of 43 years and 
mean glycosylated haemoglobin of 6.5g/dl), greater than 40% had diastolic dysfunction on 
Doppler echocardiography.47 In 1989, Shapiro et al reported a prevalence of 40% amongst a 
mixed patient population of both type1 and type2 diabetics.48 
 In a study of one-hundred and twenty Nigerian normotensive type 2 diabetic subjects, only 
29% of the diabetic subjects had normal filling function compared to 58% of the normal 
controls.49 
2.3 Clinical evidences for diabetic cardiomyopathy 
The Framingham study was the first to demonstrate an increased risk of heart failure in 
patients with diabetes mellitus.50 When the incidence of heart failure in men and women 
with diabetes mellitus was compared with that of non diabetic men and women, the 
www.intechopen.com
 
Diabetic Cardiomyopathy 
 
107 
incidence in individuals with diabetes was found to be 2- and 5-fold greater respectively.51 
Since then, additional trials like Studies of Left Ventricular Dysfunction (SOLVD),52 the 
Heart Outcomes Prevention Evaluation (HOPE) study53 and the Cardiovascular Health 
Study (CHS)54 have identified diabetes mellitus as a major risk factor for the development of 
heart failure. It has been found that close to 30% of patients with diastolic heart failure have 
diabetes mellitus.55 
Left ventricular diastolic dysfunction is proposed to be the first stage of diabetic 
cardiomyopathy.27,56 In the Strong Heart Study57 which enrolled 2,411 Native Americans, 
individuals with diabetes mellitus had evidence of impaired left ventricular relaxation on 
Doppler echocardiography. In that study, the association between diabetes mellitus and 
abnormal left ventricular relaxation was independent of age, blood pressure, LV mass and 
LV systolic function. The abnormalities were more severe in the diabetes-hypertension 
group, showing the additive deleterious effects on active LV relaxation when both of these 
conditions are present. Poirier et al58 reported that patients with well-controlled diabetes 
and without overt coronary artery disease, hypertension or heart failure have lower levels of 
exercise performance on maximal treadmill testing than do age-matched controls. This 
exercise limitation correlated with the severity of diastolic dysfunction as assessed by 
Doppler echocardiography. 
Several workers have studied the correlation between left ventricular diastolic function and 
factors such as duration of diabetes mellitus, glycaemic control, microangiopathy, 
microalbuminuria and systemic hypertension. In the study of thirty patients with type 2 
diabetes mellitus, Fiorini et al59 found no correlation between duration of diabetes mellitus 
and diastolic dysfunction.  Also, in the study of one hundred and twenty-five (125) type I 
diabetics, some workers60 found no correlation between duration of diabetes and diastolic 
dysfunction. Also, other workers61 in the study of twelve (12) type I diabetic patients found 
that diastolic abnormalities are not related to the duration of the disease. However, Bertoni 
et al62 in the study of twenty-six (26) young subjects with type 1 diabetes mellitus of at least 
three years duration, found that there is a correlation between diastolic dysfunction and 
duration of diabetes mellitus. 
In the Veterans Affairs Co-operative Study in type 2 Diabetes Mellitus (VACSDM)63, it was 
found that two years of intensive glycaemic control did not affect the left ventricular systolic 
or diastolic functions in patients with type 2 diabetes. Also in the study of twenty  
normotensive patients with a new diagnosis of type 2 diabetes mellitus, some workers64 
found that diastolic function was impaired at diagnosis and was not affected by an 
improvement in the glycaemic control.However,Felicio et al65 in the study of fifty-six 
hypertensive patients with type 2 diabetes mellitus concluded that even though there was 
no correlation between diastolic dysfunction and glycaemic control, improvement in 
glycaemic control may contribute to LVH regression in hypertensive patients with type 2 
diabetes mellitus. 
 Cecchi et al66 in the study of forty recently diagnosed type 1 diabetics (with and without 
microangiopathy) showed that slight preclinical diastolic dysfunction is present in young 
recently diagnosed type 1 diabetic without microangiopathy. But it was found that more 
severe dysfunction is present when there is also microangiopathy. Some other workers56 
confirmed this in the study of 26 young subjects with type 1 diabetes mellitus. They showed 
that there is an often sub-clinical cardiac abnormality in young diabetics resulting in 
impairment of diastolic function that is correlate with the presence of clinical complications 
such as nephropathy and retinopathy. 
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Liu et al in the strong Heart study57 showed that albuminuria is independently associated 
with LV systolic and diastolic dysfunction in type 2 diabetics. Some other workers67 in the 
study of forty-two patients with mild-to-moderate essential hypertension and type 2 
diabetes mellitus found that an elevated urinary albumin excretion is associated with an 
increased left ventricular mass index. They also found that urinary albumin excretion is 
associated with a higher prevalence of concentric left ventricular hypertrophy pattern, a 
depressed midwall systolic performance and a markedly impaired diastolic function. Also 
Mori et al68 in the study of twenty-one type 2 diabetics found that left ventricular diastolic 
function may be related to both hypertension and proteinuria.  
In the study of ten age-controlled type 2 diabetes, it was found by Poirier et al69 that left 
ventricular diastolic dysfunction and cardiac autonomic neuropathy are associated in 
patients with otherwise uncomplicated well-controlled type 2 diabetes mellitus. 
3. Pathogeesis of diabetic cardiomyopathy 
The pathogenesis of diabetic cardiomyopathy has been illustrated in figure1.The 
morphologic changes in the diabetic heart include myocyte hypertrophy, increased matrix 
collagen, interstitial fibrosis, and intra-myocardial microangiopathy.70  These changes are 
probably consequences of altered myocardial glucose and fatty acid metabolism due to 
diabetes.50 Chronic hyperglycaemia leads to nonenzymatic glycation of vascular and 
membrane proteins, producing advanced glycation end products (AGEs) and reactive 
oxygen species.67 Once AGEs develop in the arterial wall and myocardium, they form stable 
and irreversible crosslinks with adjacent collagen polymers thereby decreasing the 
compliance of the blood vessels and myocardium.67 The AGEs and reactive oxygen species 
will also affect ion channel, calcium homeostasis, and mitochondrial function, as well as 
initiating apoptosis, leading to contractile dysfunction-glucotoxicity.67 
Diabetes is also characterised by an increased turnover of free fatty acids. The increased free 
fatty acid turnover leads to increased myocardial oxygen consumption and enhances the 
intracellular accumulation of intermediates, leading to deleterious effects-lipotoxicity.67 
These effects include interference with ATP-dependent ion pumps and mobilisation of 
intracellular calcium, thereby creating calcium overload and relaxation abnormalities. 
Impaired glucose oxidation also leads to lactic acid accumulation that further promotes the 
degradation of free fatty acids.68 
Other myocardial changes in diabetes include impairment of beta-receptor signal 
transudation and induction of fetal gene pattern.70,71 The fetal gene pattern leads to 
upregulation of beta-myosin heavy chain and downregulation of alpha-myosin heavy chain 
gene which is the fast –contracting isoform of myosin heavy chain that contains much 
greater ATPase activity than does beta-myosin heavy chain.72 In addition, there is 
downregulation of the SERCA gene,73  leading to impaired myocardial calcium handling.74 
These changes in gene expression are closely associated with abnormalities in diastolic 
function.75 
To support the theory that abnormalities in high-energy phosphate metabolism may cause 
diastolic dysfunction in diabetes, magnetic resonance imaging study demonstrated LV 
diastolic dysfunction in 12 asymptomatic, normotensive, nonobese patients with well-
controlled diabetes when compared with control subjects matched for age, sex, body mass 
index, and blood pressure.76 These findings were associated with a significantly lower ratio 
of myocardial phosphocreatine to ATP in-patients with diabetes compared with controls.91 
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Results of previous studies in non-diabetic individuals with LV hypertrophy suggested that 
the lower phosphocreatine content and the switch in substrate preference from glucose to 
fatty acids may lead to lower levels of ATP in the sarcomeres that cannot be overcome by 
increased mitochondrial ATP production77. Lower cytosolic ATP concentrations are 
associated with impaired calcium sequestration by the sarcoplasmic reticulum and impaired 
relaxation of cardiomyocytes76. 
 
 
 
 
 
Increased free FA (FFA) activates PPAR- signaling, leading to the increased transcription of 
many genes involved in FA oxidation. Increased FA oxidation leads to the generation of 
ROS at the level of the electron transport chain. ROS, which also can be generated by 
extramitochondrial mechanisms such as NADPH oxidase, plays a critical role in several 
pathways involved in the pathogenesis of diabetic cardiomyopathy, including lipotoxicity, 
cell death, and tissue damage, as well as mitochondrial uncoupling and reduced cardiac 
efficiency. TG= triglycerides; GLUTs= glucose transporters; PDK4=pyruvate dehydrogenase 
kinase 4; MCD=malonyl-coenzyme A decarboxylase;MCoA= malonyl-coenzyme A; 
ACoA=acetyl-coenzyme A; ACC= acetyl coenzyme A carboxylase; CPT1= carnitine 
palmitoyl-transferase 1; PDH= pyruvate dehydrogenase; CE= cardiac efficiency; PKC= 
protein kinase C; and AGE= glycation end products 
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4. Diagnosing diastolic dysfunction 
Differentiating between diastolic and systolic dysfunction on clinical grounds is very difficult, 
although clues may be given by the patient’s past history, clinical presentation, physical 
examination, radiographic and electrocardiographic findings.78 Exertional dyspnoea because 
of pulmonary congestion is frequently an early event in diastolic dysfunction.78 
More commonly, estimates of left ventricular size and systolic function are needed in order 
to determine whether congestive heart failure is caused by systolic or diastolic dysfunction. 
These measurements can be made using echocardiography, radionuclide ventriculography, 
or contrast ventriculography.79 
Precisely, the definite diagnosis of diastolic dysfunction or failure depends on the 
observation of an appropriate upward shift of the (end-) diastolic pressure – volume 
relation.80 Therefore, objective evidence of ventricular diastolic dysfunction requires cardiac 
catheterisation with volume determinations using frame-by-frame analysis of left 
ventricular contrast angiograms or impedance measurements and high – fidelity 
measurements of ventricular pressure with a micromanometer.81  However, due to the 
invasive nature, high cost, and limited availability of haemodynamic studies, this remains 
impractical for widespread use or for serial follow-up examinations82 thereby leaving 
echocardiography as the gold standard. 
4.1 Echocardiography 
Doppler echocardiography has become the most widely used and accepted method for the 
diagnosis and follow-up of patients with diastolic dysfunction. Its reliability, 
reproducibility, ease of performance, and advances in applications over the past decade 
makes it the ideal tool for the assessment of “diastology”83. The basis of the Doppler 
echocardiographic assessment of diastolic function relies on a careful, integrated 
approach.84,85 The main stay of this approach involves the recording of flow velocities across 
the mitral valve and within the pulmonary veins to assess filling patterns and estimate left 
ventricular filling pressure indirectly.85 Mitral flow velocities are obtained by pulse-wave 
Doppler echocardiography placing the sample volume located between the tips of the mitral 
valve leaflet during ventricular diastole (as shown in figure 2). The peak velocity of early 
rapid filling (E), peak velocity of late filling caused by atrial contraction (A), E/A ratio, the 
interval from the peak of E velocity to its extrapolation to baseline or the deceleration time 
(DT) and the interval from aortic valve closure to mitral valve opening or isovolumic 
relaxation time (IVRT) is measured.86 
Pulmonary venous flow is measured using pulse-wave Doppler echocardiography with 
sample volume located 1-2cm into a pulmonary vein, proximal to its insertion into the left 
atrium(as shown in figure 3). The systolic peak velocity which is biphasic in 30% of cases (S), 
diastolic peak velocity (D), the S/D ratio, atrial systolic reversal velocity (A) are measured.87 
Based on Doppler echocardiographic studies, diastolic filling is classified into:86 normal, 
impaired relaxation or mild diastolic dysfunction, moderate diastolic dysfunction or pseudo 
normal filling and severe diastolic dysfunction or restrictive filling. 
4.2 Normal filling 
The determinants of LV filling, ventricular relaxation and effective chamber compliance 
change with increasing age. This leads to different diastolic filling patterns for different 
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groups.88 In normal young individuals aged (20s – 30s), LV relaxation is rapid, the majority 
of filling (85-95%) occurring in early diastole and only a small proportion (5-15%) occurring 
with atrial contraction. This results in mitral inflow parameters of E/A between 1-2 
(mean1.8), and relatively short deceleration time (mean 182msec) and isovolumetric 
relaxation time (mean 71msec).  Pulmonary venous inflow usually shows a slight systolic 
predominance (S>D) with a mean pulmonary ‘A’ of 0.19m/sec.89 
 
 
RV =Right Ventricle 
LV=Left Ventricle 
RA=Right Atrium 
LA =Left Atrium 
SV=Sample Volume 
AMVL=Anterior Mitral Valve Leaflet 
PMVL=Posterior Mitral Valve Leaflet 
E=Mitral E wave 
A=Mitral A wave 
Fig. 2.Echocardiogram showing measurement of Transmitral Flow Velocity Profile ('E' and 
‘A’ Waves) 
With aging, the rate of LV relaxation decreases with slower and less filling in early diastole 
and an increased contribution to LV filling by atrial contraction. This leads to a prolongation 
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of the IVRT and DT, a reduction in E velocity, and an increase in A velocity with a 
subsequent reduction in E/A ratio. Individuals >65 years have the following average 
parameters: E/A ratio of less than 1, a mean DT greater than 214msec, and IVRT greater 
than of 94msec. As pulmonary D parallels the pulmonary S velocity, the pulmonary venous 
flow now shows diastolic predominance (D>S). As well, the A increases slightly, but does 
not exceed the upper limit of normal (0.35m/sec).90 
 
 
LV=Left Ventricle,  
RV =Right Ventricle, 
RA=Right Atrium, 
A =Left Atrium,  
SV=Sample Volume,  
UPV= Upper Pulmonary Vein (Right),  
S=Pulmonary Vein Systolic Velocity, 
D=Pulmonary Vein Diastolic velocity,  
A=Pulmonary Reverse flow Velocity 
Fig. 3. Echocardiogram showing measurement of Pulmonary Flow Velocity Profile 
4.3 Mild diastolic dysfunction 
This represents the earliest stage of diastolic dysfunction. There is impaired LV relaxation 
with initially normal LV filling pressures, leading to decreased early filling and increased 
filling with atrial contraction. Mitral inflow patterns show an E/A less than 1 which is 
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abnormal for the age. The IVRT is prolonged (>100msec), with prolongation of the DT 
(>200msec). Pulmonary venous inflow normally remains normal with systolic 
predominance (S>D), and with pulmonary ‘A’<0.35m/sec.90 
4.4 Moderate diastolic dysfunction 
As diastolic dysfunction progresses, LV relaxation becomes further impaired and LV 
stiffness increases.90 In an attempt to maintain LV filling and cardiac output, the filling 
pressure, specifically left atrial (LA) pressure becomes elevated.  This increased transmitral 
pressure gradient leads to increased early filling with the E/A ratio ‘normalizing’ to a value 
>1, with prolongation of IVRT and DT to high values. This mitral pattern is similar to the 
pattern in normal individuals, leading to the term ‘pseudonormal’.  The differentiation from 
normal is done on the basis of an abnormal response to the valsalva manoeuvre or as 
abnormal pulmonary venous flow pattern.90 
4.5 Severe diastolic dysfunction 
As diastolic dysfunction progresses further, LV relaxation continues to be impaired, 
however, it is marked by rising LV filling pressures and a markedly reduced LV 
compliance. This mimics the physiology of restrictive cardiomyopathy.90 The increased LA 
pressure causes an early mitral valve opening and rapid early filling (increased E velocity). 
As early rapid filling occur into a noncompliant LV, there is rapid equalization of LV and 
LA pressured leading to a shortened DT.90 Atrial contraction into a noncompliant LV with 
high diastolic pressure leads to a reduced A velocity. Therefore, the E/A ratio is >2, and 
occasionally >4 to 5. Pulmonary venous inflow shows a marked blunting of systolic inflow 
(PS<<PD) corresponding to the markedly elevated LA pressure and reduced LA 
compliance.87 
5. Conclusion 
Abnormal left ventricular relaxation seen in diabetics, independent of other factors has been 
shown to contribute to the incidence of congestive heart failure despite normal left 
ventricular ejection fraction.55 It is therefore another cause of clinical cardiovascular 
morbidity. In addition, reduced or increased mitral E/A ratio has been shown to be 
independently associated with increased all cause mortality as well as cardiovascular 
mortality.91 
It is therefore necessary to detect early, diabetic patients with left ventricular diastolic 
dysfunction and commence treatment modalities such as use of selective β – blockers and 
ACE inhibitor.131 However, there have not been prospective intervention studies to 
determine the reversibility and effectiveness of such treatments. 
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